From L-R: Arda Therapeutics chief technology officer Remi-Martin Laberge, CEO Adam Freund and CSO Scott Turner
October 8, 2024 07:30 AM EDTUpdated October 9, 05:32 PM
Financing
Startups

Ex­clu­sive: Lil­ly backs a16z-fund­ed Ar­da Ther­a­peu­tic­s' $43M Se­ries A to take AD­Cs in­to fi­bro­sis

Kyle LaHucik

Senior Reporter

A three-year-old start­up based on decades of re­search in cell de­ple­tion is bet­ting that some of the hottest tools in on­col­o­gy may work even bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times